NKGen Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Net Income	-82.95	-26.75	-23.27
Depreciation & Amortization	1.57	1.65	1.24
Share-Based Compensation	4.14	0.07	0.09
Other Operating Activities	55.31	2.48	2.38
Operating Cash Flow	-21.95	-22.56	-19.55
Capital Expenditures	-0.05	-0.16	-0.46
Investing Cash Flow	-0.05	-0.16	-0.46
Share Issuance / Repurchase	11.89	0.16	0.06
Debt Issued / Paid	26.11	22.33	20.1
Other Financing Activities	-15.84	-	-
Financing Cash Flow	22.16	22.49	20.16
Net Cash Flow	0.16	-0.23	0.15
Free Cash Flow	-22	-22.72	-20.01
Free Cash Flow Margin	-	-29506.49%	-4696.48%
Free Cash Flow Per Share	-1.43	-3.57	-1.40

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).